GSK CFO Points to Cancer Drugs to Bridge £3.4 Billion Sales Forecast Gap

GSK logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Oncology is GSK’s main opportunity to narrow the roughly £3.4 billion gap between analysts’ 2031 sales consensus of £36.6 billion and the company’s target of more than £40 billion. CFO Julie Brown pointed to the experimental B7-H3 drug Ris-Rez and said upcoming data and launches could affect forecasts.
  • GSK plans to accelerate development, targeting 22 Phase III trial starts by year-end, versus about seven last year. Its cost program aims to deliver £1.9 billion in annual savings by 2029, with most savings directed to R&D.
  • New products and growth in oncology and other specialty areas are intended to help offset dolutegravir patent expirations starting in 2028. GSK also expects to consider further $2 billion–$4 billion acquisitions and says it has capacity for deals despite higher debt.
  • Five stocks to consider instead of GSK.

GSK NYSE: GSK Chief Financial Officer Julie Brown said oncology products could help close the gap between analysts’ sales expectations and the company’s target of more than £40 billion in annual sales by 2031, as it accelerates drug development and cuts costs.

Speaking at the 2026 U.K. Leaders Conference, Brown said GSK expects to complete 22 Phase III trial starts by the end of the year, compared with about seven last year and six the year before. The company’s Accelerate Growth program, announced in July, aims to generate £1.9 billion in annual savings by 2029, with most of the money directed toward research and development.

Brown said the company’s 2031 sales guidance accounts for the probability of technical and regulatory success. JPMorgan’s Zain Ebrahim said consensus estimates for that year were about £36.6 billion.

“The biggest difference, if I was to isolate it, would be in oncology,” Brown said, noting that GSK has been building its presence in the field. She highlighted an experimental B7-H3 treatment, known as Ris-Rez, and said data over the next two or three years, along with the performance of products in or near launch, could influence consensus forecasts.

Cost savings and dealmaking

Brown said the savings program was progressing potentially ahead of schedule. GSK has said it expects to deliver 90% of the £1.9 billion target by 2028. Savings are expected to come from streamlining support functions and the supply chain, as well as using technology and artificial intelligence.

Some savings could also support margins as the company faces dolutegravir patent expirations from 2028 to 2030. Brown said GSK expects margins to be stable to improving through that period, with decisions on how much to retain for investment to come closer to the time.

On business development, Brown said GSK would probably continue looking at deals in the $2 billion to $4 billion range after its Nuvalent acquisition. She said pro forma net debt to EBITDA was 1.8 times at the end of September, up from about 1.3 times last year, but that the company still had room for further deals.

GSK is tracking toward its guidance for more than £10 billion in cash generated from operations this year, measured at last year’s exchange rates, she said.

Launches and HIV transition

Brown highlighted several products in or near launch, including severe asthma treatment Exdensur, hepatitis B treatment Hibsago and multiple myeloma treatment Blenrep. She said Exdensur had received more than 40 approvals worldwide and that U.S. reimbursement barriers had started to ease, potentially supporting sales in the fourth quarter and into next year.

For Hibsago, Brown said uptake was difficult to forecast and would differ by market. Japan has established hepatitis B testing and treatment, while affordability and pricing are considerations in China. In the U.S., she said, broader testing would be important; patients also need weekly blood monitoring.

In HIV, Brown said GSK plans to update investors most probably with its full-year results following discussions with the U.S. Food and Drug Administration about data for a four-monthly prevention option. She said those data do not have a direct read-through to the company’s four-monthly treatment study or its separate six-monthly programs.

Brown expects long-acting HIV injections to provide some protection against sales erosion from dolutegravir patent expirations, but not to replace those sales completely. Growth in oncology, respiratory and other specialty products is intended to help offset the pressure, she said.

About GSK (NYSE:GSK)

GSK plc is a global biopharmaceutical company headquartered in the United Kingdom. It researches, develops and manufactures medicines and vaccines, with a focus on areas including infectious diseases, HIV, respiratory and immune conditions, and cancer. Its products include vaccines such as Shingrix, which helps prevent shingles, and Arexvy, for respiratory syncytial virus (RSV). GSK also makes specialty medicines, including treatments for HIV and respiratory diseases, and continues to develop new medicines and vaccines through its research programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in GSK Right Now?

Before you consider GSK, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.

While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines